You are here

Article Text

Article menu
Download PDFPDF
Prevention
Systematic review
Vaccination of older adults against herpes zoster is safe and effective
  1. Stephen K Tyring
  1. Department of Dermatology, University of Texas, Houston, Texas, USA
  1. Correspondence to : Dr Stephen K Tyring
    Department of Dermatology, University of Texas, 451 North Texas Ave, Houston, TX 77598, USA; styring{at}ccstexas.com

https://doi.org/10.1136/eb-2012-101138

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Gagliardi AM, Gomes Silva BN, Torloni MR, et al. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev 2012;10:CD008858.

    Context

    The problem addressed by this study is that older individuals, for example, those over 60 years of age, are more likely to develop herpes zoster (HZ) than younger people. Older adults are far more likely to develop severe complications of HZ, especially postherpetic neuralgia (PHN).

    Methods

    Gagliardi and colleagues reviewed eight randomised controlled trials (RCTs) involving 52 269 participants.

    Findings

    By focusing on RCTs and assessing the risk of bias in these studies, the authors concluded that vaccination against HZ is safe and effective. The risk of HZ was less compared to placebo: risk ratio (RR) 0.49 (95% CI 0.43 to 0.56), with a …

    View Full Text

    Footnotes

    • Competing interests SKT has worked on clinical trials that have been sponsored by the manufacturer of Zostavax, Merck.